Karen Savage

Dr. Karen Savage

Swinburne University of Technology, Melbourne, Victoria, Australia
+2
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2017 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
KSKaren Savage
Karen Savage
JFJoseph Firth
Joseph Firth
CSCon Stough
Con Stough
JSJerome Sarris
Jerome Sarris

13 July 2022 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
MFMasoumeh Tangestani Fard
Masoumeh Tangestani Fard
KSKaren Savage
Karen Savage
CSCon K. Stough
Con K. Stough

24 December 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MKMrudhula Komanduri
Mrudhula Komanduri
KSKaren Savage
Karen Savage
ALAna Lea
Ana Lea
GMGrace McPhee
Grace McPhee
KNKaren Nolidin
Karen Nolidin
SGShakuntla Gondalia
Shakuntla Gondalia
Ageing is associated with changes in biological processes, including reductions in cognitive functions and gut microbiome diversity. However, not much is known about the relationship between cognition and the microbiome with increasing age. Therefore, we examined the relationship between the gut microbiome and cognition in 69 healthy participants aged 60–75 years. The gut microbiome was analysed with the 16S rRNA sequencing method. The cognitive assessment included the Cognitive Drug Research computerised assessment battery, which produced five cognitive factors corresponding to ‘Quality of Episodic Secondary Memory’, ‘Quality of Working Memory’, ‘Continuity of Attention, ‘Speed of Memory’ and ‘Power of Concentration’. Multiple linear regression showed that the bacterial family Carnobacteriaceae explained 9% of the variance in predicting Quality of Episodic Secondary Memory. Alcaligenaceae and Clostridiaceae explained 15% of the variance in predicting Quality of Working Memory; Bacteroidaceae, Barnesiellaceae, Rikenellaceae and Gemellaceae explained 11% of the variance in Power of Concentration. The present study provides specific evidence of a relationship between specific families of bacteria and different domains of cognition.

1 December 2020 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
KPKimberley Kira Petrov
Kimberley Kira Petrov
AHAmie Hayley
Amie Hayley
SCSarah Catchlove
Sarah Catchlove
KSKaren Savage
Karen Savage
CSCon Stough
Con Stough

2 May 2023 in Experimental Gerontology
Verified
Journal Article
Open access
KSKaren Savage
Karen Savage
CPClaire Porter
Claire Porter
EBEmily Bunnett
Emily Bunnett
MHMaher Hana
Maher Hana
AKAndrew Keegan
Andrew Keegan
APAndrew Pipingas
Andrew Pipingas

28 October 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
KSKaren Savage
Karen Savage
JSJerome Sarris
Jerome Sarris
MHMatthew Hughes
Matthew Hughes
CBChad Bousman
Chad Bousman
SRSusan Rossell
Susan Rossell
CSChao Suo
Chao Suo
Generalised Anxiety Disorder (GAD) is a prevalent, chronic mental health disorder. The measurement of regional brain gamma-aminobutyric acid (GABA) offers insight into its role in anxiety and is a potential biomarker for treatment response. Research literature suggests Piper methysticum (Kava) is efficacious as an anxiety treatment, but no study has assessed its effects on central GABA levels. This study investigated dorsal anterior cingulate (dACC) GABA levels in 37 adult participants with GAD. GABA was measured using proton magnetic resonance spectroscopy (1H-MRS) at baseline and following an eight-week administration of Kava (standardised to 120 mg kavalactones twice daily) (n = 20) or placebo (n = 17). This study was part of the Kava for the Treatment of GAD (KGAD; ClinicalTrials.gov: NCT02219880), a 16-week intervention study. Compared with the placebo group, the Kava group had a significant reduction in dACC GABA (p = 0.049) at eight weeks. Baseline anxiety scores on the HAM-A were positively correlated with GABA levels but were not significantly related to treatment. Central GABA reductions following Kava treatment may signal an inhibitory effect, which, if considered efficacious, suggests that GABA levels are modulated by Kava, independent of reported anxiety symptoms. dACC GABA patterns suggest a functional role of higher levels in clinical anxiety but warrants further research for symptom benefit. Findings suggest that dACC GABA levels previously un-examined in GAD could serve as a biomarker for diagnosis and treatment response.